Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has ...

However, analysts from Cantor Fitzgerald, Oppenheimer, and JPMorgan were among those to reiterate their buy-equivalent ratings on Regeneron (NASDAQ:REGN) despite the trial setback. “We do still ...

The disappointing guidance spurred a downgrade at JPMorgan. - Regeneron Pharmaceuticals (REGN) shares slump after Wells Fargo Securities cut the recommendation on Regeneron Pharmaceuticals Inc. to ...

The S&P 500 slipped less than 0.1% on Friday, May 30, 2025, as President Trump rekindled his tough rhetoric on China and a ...

Regeneron Pharmaceuticals (REGN ... declined as the maker of contact lenses cut its full-year organic growth outlook and JPMorgan downgraded the stock and lowered its price target on concerns about ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

Fintel reports that on May 30, 2025, Wells Fargo downgraded their outlook for Regeneron Pharmaceuticals (BMV:REGN) from Overweight to Equal-Weight. Jpmorgan Chase holds 5,658K shares representing ...